Literature DB >> 19887833

Is cystatin C a useful marker in the detection of diabetic kidney disease?

Rodolfo L Borges1, Andréa H Hirota, Beata M R Quinto, Arthur B Ribeiro, Maria T Zanella, Marcelo C Batista.   

Abstract

BACKGROUND/AIMS: To evaluate cystatin C as a marker of diabetic kidney disease in normoalbuminuric diabetic patients without chronic kidney disease (CKD).
METHODS: A cross- sectional study was carried out comprising 243 hypertensive patients, 61 of them with type 2 diabetes, presenting normoalbuminuria and an estimated glomerular filtration rate (eGFR) >or=60 ml/min/1.73 m(2). Renal function assessment included determinations of serum creatinine and cystatin C levels, microalbuminuria, as well as eGFR through Cockcroft-Gault and Modification of Diet in Renal Disease equations.
RESULTS: Diabetic patients presented higher cystatin C levels than nondiabetic patients (0.95 +/- 0.19 vs. 0.89 +/- 0.17 mg/l; p < 0.05). In the binary logistic regression, the presence of diabetes and metabolic syndrome was significantly associated with elevated cystatin C levels. Diabetic patients also presented a slightly greater albuminuria (6.72 +/- 4.43 vs. 5.07 +/- 3.59 microg/min; p < 0.05).
CONCLUSIONS: Our results suggest that elevated cystatin C levels in diabetic patients may identify a certain degree of renal dysfunction even when albuminuria and eGFR do not mirror CKD. Longitudinal studies with direct GFR measures need to be done in order to confirm the value of cystatin C as an indicative of worse renal outcomes in the diabetic population. (c) 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19887833     DOI: 10.1159/000254385

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  6 in total

1.  Early Detection of Renal Impairment Among Patients with Type 2 Diabetes Mellitus Through Evaluation of Serum Cystatin C in Comparison with Serum Creatinine Levels: A Cross-Sectional Study.

Authors:  Tadesse Asmamaw; Solomon Genet; Menakath Menon; Getahun Tarekegn; Endeshaw Chekol; Zeleke Geto; Tadesse Lejisa; Wossene Habtu; Tigist Getahun; Yosef Tolcha
Journal:  Diabetes Metab Syndr Obes       Date:  2020-12-03       Impact factor: 3.168

2.  Exercise electrocardiographic responses and serum cystatin C levels among metabolic syndrome patients without overt diabetes mellitus.

Authors:  Asli Tanindi; Hilal Olgun; Ayse Tuncel; Bulent Celik; Hatice Pasaoglu; Bulent Boyaci
Journal:  Vasc Health Risk Manag       Date:  2011-02-06

3.  Proximal tubule dysfunction is associated with podocyte damage biomarkers nephrin and vascular endothelial growth factor in type 2 diabetes mellitus patients: a cross-sectional study.

Authors:  Ligia Petrica; Adrian Vlad; Gheorghe Gluhovschi; Florica Gadalean; Victor Dumitrascu; Cristina Gluhovschi; Silvia Velciov; Flaviu Bob; Daliborca Vlad; Roxana Popescu; Oana Milas; Sorin Ursoniu
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

Review 4.  Establishing the presence or absence of chronic kidney disease: Uses and limitations of formulas estimating the glomerular filtration rate.

Authors:  Ahmed Alaini; Deepak Malhotra; Helbert Rondon-Berrios; Christos P Argyropoulos; Zeid J Khitan; Dominic S C Raj; Mark Rohrscheib; Joseph I Shapiro; Antonios H Tzamaloukas
Journal:  World J Methodol       Date:  2017-09-26

5.  The effect of glucocorticoids on serum cystatin C in identifying acute kidney injury: a propensity-matched cohort study.

Authors:  Silin Liang; Mai Shi; Yunpeng Bai; Yujun Deng; Miaoxian Fang; Jiaxin Li; Yijin Wu; Wenying Peng; Yating Hou; Heng Fang; Huidan Zhang; Chunbo Chen
Journal:  BMC Nephrol       Date:  2020-11-27       Impact factor: 2.388

6.  Divergence between serum creatine and cystatin C in estimating glomerular filtration rate of critically ill COVID-19 patients.

Authors:  Yanan Liu; Peng Xia; Wei Cao; Zhengyin Liu; Jie Ma; Ke Zheng; Limeng Chen; Xuewang Li; Yan Qin; Xuemei Li
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.